The global hepatitis testing/diagnosis market was valued at USD 2.6 billion in 2021 and it is anticipated to reach up to USD 4.4 billion by 2031, at a CAGR of 5.5% during the forecast period.
The goal of hepatitis diagnosis is to identify the genotype of the infection that is causing the condition. The optimal course of treatment for the patient can be chosen based on the hepatitis diagnosis. In order to distinguish between different hepatitis viruses, it is crucial to make a diagnosis of the illness. Inflammation in the liver is the primary cause of hepatitis. Different forms of the hepatitis virus, including Hepatitis A, B, and C, are recognized. Blood tests are used to identify the presence of hepatitis disease. Testing bodily proteins or genetic material that is a component of the virus can also be used to identify hepatitis.
To Remain ‘Ahead’ Of Your Competitors, Request for A Sample –https://www.globalinsightservices.com/request-sample/GIS10295
Market Trends and Drivers
Despite substantial advancements in treatment options, immunization coverage, and public awareness, hepatitis remains a serious public health concern with a high prevalence rate worldwide. The most common hepatitis forms, B and C, are associated with greater fatality rates. According to estimates, 296 million and 58 million persons, respectively, had chronic HBV and HCV infections in 2019. Compared to industrialized countries, hepatitis is more common in poor nations. Similarly, the biotechnology and biopharmaceutical industries have a significant demand for immunoassay equipment and supplies.
Therefore, over the forecast period, the expansion of these industries is anticipated to boost the expansion of the hepatitis testing market. The expansion of the end-user market in these sectors has prompted numerous businesses to introduce new products and make investments in the development of cutting-edge products. Since immunoassays are used throughout the production process, from product development and manufacturing to quality control, this is regarded as a promising sign for the market’s expansion.
Get A Customized Scope to Match, Your Need Ask an Expert –https://www.globalinsightservices.com/request-customization/GIS10295
Global Hepatitis Testing/Diagnosis Market Segmentation
By Disease Type
- Hepatitis B
- Hepatitis C
- Other Hepatitis
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Rapid Diagnostic Tests (RDT)
- Polymerase Chain Reaction (PCR)
- Isothermal Nucleic Acid Amplification Technology (INAAT)
- Other Technologies
By End User
- Hospital & Diagnostic Laboratories
- Blood Banks
- Other End Users
For In-Depth Competitive Analysis, Purchase this Report –https://www.globalinsightservices.com/checkout/single_user/GIS10295
Major Players in the Global Hepatitis Testing/Diagnosis Market
The key players studied in the market are F. Hoffmann-La Roche Ltd. (Switzerland), Abbott Laboratories (US), Siemens Healthineers AG (Germany), Bio-Rad Laboratories, Inc. (US), Danaher Corporation (US), QIAGEN (Netherlands), bioMérieux SA (France), DiaSorin S.P.A. (Italy), Ortho Clinical Diagnostics (US), MedMira Inc. (Canada), and Fujirebio US, Inc. (Japan) among others.
New Report Published by Global Insight Services: https://www.globalinsightservices.com/reports/hydrogen-projects-database/
About Global Insight Services:
Global Insight Services (GIS) is a leading multi-industry market research firm headquartered in Delaware, US. We are committed to providing our clients with highest quality data, analysis, and tools to meet all their market research needs. With GIS, you can be assured of the quality of the deliverables, robust & transparent research methodology, and superior service.
Global Insight Services LLC
16192, Coastal Highway, Lewes DE 19958
E-mail: [email protected]